title: Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.
abstract: The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.
authors.affiliation: Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Supersaxo
authors.forename: W
authors.initials: W
authors.lastname: Hein
authors.forename: H
authors.initials: H
authors.lastname: Gallati
authors.forename: H
authors.initials: H
authors.lastname: Steffen
mesh_terms: D000042:Absorption; D000818:Animals; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000378:metabolism*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D008196:Lymph / Q000378:metabolism; D008221:Lymphoid Tissue / Q000378:metabolism*; D011994:Recombinant Proteins; D012709:Serum Albumin / Q000378:metabolism; D012756:Sheep; D013997:Time Factors
chemical_list: D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012709:Serum Albumin